Abstract
Prostate cancer (PCa) is the second most prevalent malignancy among men worldwide. The aberrant activation of androgen receptor (AR) signaling has been recognized as a crucial oncogenic driver for PCa and AR antagonists are widely used in PCa therapy. To develop novel AR antagonist, a machine-learning MIEC-SVM model was established for the virtual screening and 51 candidates were selected and submitted for bioactivity evaluation. To our surprise, a new-scaffold AR antagonist C2 with comparable bioactivity with Enz was identified at the initial round of screening. C2 showed pronounced inhibition on the transcriptional function (IC50 = 0.63 μM) and nuclear translocation of AR and significant antiproliferative and antimetastatic activity on PCa cell line of LNCaP. In addition, C2 exhibited a stronger ability to block the cell cycle of LNCaP than Enz at lower dose and superior AR specificity. Our study highlights the success of MIEC-SVM in discovering AR antagonists, and compound C2 presents a promising new scaffold for the development of AR-targeted therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32:1105–40.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Prim. 2021;7:9.
Li D, Zhou WF, Pang JP, Tang Q, Zhong BL, Shen C, et al. A magic drug target: androgen receptor. Med Res Rev. 2019;39:1485–514.
Lv S, Song Q, Chen G, Cheng E, Chen W, Cole R, et al. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. J Clin Invest. 2021;131:e141335.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.
Zhang B, Zhang M, Yang Y, Li Q, Yu J, Zhu S, et al. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC. Oncogene. 2022;41:387–99.
Chai X, Sun H, Zhou W, Chen C, Shan L, Yang Y, et al. Discovery of N-(4-(Benzyloxy)-phenyl)-sulfonamide derivatives as novel antagonists of the human androgen receptor targeting the activation function 2. J Med Chem. 2022;65:2507–21.
Zhou W, Duan M, Fu W, Pang J, Tang Q, Sun H, et al. Discovery of novel androgen receptor ligands by structure-based virtual screening and bioassays. Genom Proteom Bioinform. 2018;16:416–27.
Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, et al. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem Biol. 2014;21:1476–85.
Fu W, Yang H, Hu C, Liao J, Gong Z, Zhang M, et al. Small-molecule inhibition of androgen receptor dimerization as a strategy against prostate cancer. ACS Cent Sci. 2023;9:675–84.
Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 2000;7:211–47.
Kim W, Ryan CJ. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol. 2012;13:189–200.
Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
Bambury RM, Scher HI. Enzalutamide: development from bench to bedside. Urol Oncol. 2015;33:280–8.
Song CH, Yang SH, Park E, Cho SH, Gong EY, Khadka DB, et al. Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem. 2012;287:30769–80.
Tang Q, Fu W, Zhang M, Wang E, Shan L, Chai X, et al. Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation. Eur J Med Chem. 2020;192:112156.
Fu W, Zhang M, Liao J, Tang Q, Lei Y, Gong Z, et al. Discovery of a novel androgen receptor antagonist manifesting evidence to disrupt the dimerization of the ligand-binding domain via attenuating the hydrogen-bonding network between the two monomers. J Med Chem. 2021;64:17221–38.
Hard R, Li N, He W, Ross B, Mo GCH, Peng Q, et al. Deciphering and engineering chromodomain-methyllysine peptide recognition. Sci Adv. 2018;4:eaau1447.
Hou T, Zhang W, Case DA, Wang W. Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. J Mol Biol. 2008;376:1201–14.
Hou T, Xu Z, Zhang W, McLaughlin WA, Case DA, Xu Y, et al. Characterization of domain-peptide interaction interface: a generic structure-based model to decipher the binding specificity of SH3 domains. Mol Cell Proteom. 2009;8:639–49.
Hou TJ, Li N, Li YY, Wang W. Characterization of domain-peptide interaction interface: prediction of SH3 domain-mediated protein-protein interaction network in yeast by generic structure-based models. J Proteome Res. 2012;11:2982–95.
Sun H, Pan P, Tian S, Xu L, Kong X, Li Y, et al. Constructing and validating high-performance MIEC-SVM models in virtual screening for kinases: a better way for actives discovery. Sci Rep. 2016;6:24817.
Wang Q, Wang Z, Tian S, Wang L, Tang R, Yu Y, et al. Determination of molecule category of ligands targeting the ligand-binding pocket of nuclear receptors with structural elucidation and machine learning. J Chem Inf Model 2022;62:3993–4007.
Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA. 2005;102:6201–6.
Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities. Nucleic Acids Res. 2007;35:D198–D201.
Schrödinger, version 9.0, Schrödinger, LLC, New York, NY, 2009. http://www.schrodinger.com.
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem. 2006;49:6177–96.
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47:1750–9.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47:1739–49.
Wang J, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J Comput Chem. 2000;21:1049–74.
Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157–74.
Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem. 2002;23:1623–41.
Xu L, Sun H, Li Y, Wang J, Hou T. Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. J Phys Chem B. 2013;117:8408–21.
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–35.
Darden T, York D, Pedersen L. Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys. 1993;98:10089–92.
Tang R, Chen P, Wang Z, Wang L, Hao H, Hou T, et al. Characterizing the stabilization effects of stabilizers in protein–protein systems with end-point binding free energy calculations. Brief Bioinform. 2022;23:bbac127.
Yu Y, Wang Z, Wang L, Tian S, Hou T, Sun H. Predicting the mutation effects of protein-ligand interactions via end-point binding free energy calculations: strategies and analyses. J Cheminform. 2022;14:56.
Onufriev A, Bashford D, Case DA. Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins Struct Funct Bioinform. 2004;55:383–94.
Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol. 2003;330:891–914.
Miller III BR, McGee TD, Swails JM, Homeyer N, Gohlke H, Roitberg AE. J Chem Theory Comput. Vol. 8, 3314–21 (2012).
Vapnik V. The nature of statistical learning theory (Springer Science & Business Media, 2013).
Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20:273–97.
Chang C-C, Lin C-J. LIBSVM: a library for support vector machines. ACM Trans Intell Syst Technol. 2001;2:1–27.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.
Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014;33:413–27.
Acknowledgements
This research was supported by Zhejiang Provincial Natural Science Foundation of China (LD22H300001, 2023C03110) and the National Natural Science Foundation of China (U21A20301).
Author information
Authors and Affiliations
Contributions
DL, TJH, and HYS initiated and supervised the research. XYW, XC, and HYS conducted virtual screening, compound validations and biological assays. LHS, XHX, and LX performed part of in vitro experiments and interpreted part of the data. XYW, XC, HYS, and DL wrote the manuscript, and other authors contributed specific parts of the manuscript. HYS and DL assume responsibility for the manuscript in its entirety. All authors have given approval to the final version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, Xy., Chai, X., Shan, Lh. et al. A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model. Acta Pharmacol Sin (2024). https://doi.org/10.1038/s41401-024-01284-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41401-024-01284-x